Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 17/20 | 1.00 |
| ▸ | CA2 | P00918 | 17/20 | 1.00 |
| ▸ | CA9 | Q16790 | 17/20 | 1.00 |
| ▸ | CA4 | P22748 | 16/20 | 1.00 |
| ▸ | CA7 | P43166 | 16/20 | 1.00 |
| ▸ | CA1 | P00915 | 16/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.50 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.47 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766441 | 1.00 | CA12 (1.00) | CA12CA2CA9CA4CA7 | |
| SCHEMBL9768723 | 0.80 | CA12 (0.67) | CA12CA2CA9CA4CA7 | |
| SCHEMBL8336188 | 0.79 | CA12 (0.64) | CA12CA2CA9CA4CA7 | |
| SCHEMBL18967017 | 0.77 | CA12 (0.62) | CA12CA2CA9CA4CA7 | |
| SCHEMBL6553217 | 0.77 | CA12 (0.62) | CA12CA2CA9CA4CA7 | |
| SCHEMBL9283155 | 0.76 | CA2 (0.62) | CA12CA2CA9CA4CA7 | |
| SCHEMBL16277684 | 0.75 | CA12 (1.00) | CA12CA2CA9CA4CA7 | |
| SCHEMBL375359 | 0.75 | CA12 (1.00) | CA12CA2CA9CA4CA7 | |
| SCHEMBL8492205 | 0.75 | CA12 (1.00) | CA12CA2CA9CA4CA7 | |
| SCHEMBL29766350 | 0.75 | CA12 (1.00) | CA12CA2CA9CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007760-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-31 | — | — | EP | claimed |
| WO-2007108569-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-09-27 | — | — | WO | claimed |
| US-20250289792-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | SOLENT THERAPEUTICS LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-12247015-B2 | 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2 | SOLENT THERAPEUTICS, LLC (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230219912-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| US-20220119361-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | SOLENT THERAPEUTICS, LLC | 2022-04-21 | — | — | US | disclosed |
| EP-3962901-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | Solent Therapeutics, LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2021236818-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2020223255-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | SOLENT THERAPEUTICS, LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| WO-2019031981-A1 | HEPATITIS VIRUS ENTRY INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS | ИВАЩЕНКО, Александр Васильевич | 2019-02-14 | — | — | WO | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
| EP-0906297-B1 | 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | UNIV LIEGE (BE) | 2004-02-25 | — | — | EP | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
| WO-1999032467-A1 | 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-07-01 | — | — | WO | disclosed |
| EP-0687178-A1 | USE OF 2H-1,2,4-BENZOTHIADIAZINE 3(4H)-ONE 1,1 DIOXIDE DERIVATIVES AS NON-COMPETITIVE NMDA RECEPTOR ANTAGONISTS | Aventis Pharma S.A. (FR) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020109-A1 | USE OF 2H-1,2,4-BENZOTHIADIAZINE 3(4H)-ONE 1,1 DIOXIDE DERIVATIVES AS NON-COMPETITIVE NMDA RECEPTOR ANTAGONISTS | RHONE-POULENC RORER S.A. (FR) | 1994-09-15 | — | — | WO | disclosed |
| WO-1993023064-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF THROMBOSIS | THOMAS JEFFERSON UNIVERSITY (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0268990-A2 | New benzothiadiazine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-01 | — | — | EP | disclosed |
| US-4029780-A | HYPOTENSIVE AGENT FREE OF SIDE-EFFECTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JA) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247015-B2 | 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2 | TPX2, MRGPRX2, CBX2 | CA12 4699/4885CA2 1458/4885CA9 4071/4885 |
| US-10316028-B2 | Orexin receptor antagonists | HCRTR2, HCRTR1, NPY4R | CA12 3688/4885CA2 2051/4885CA9 4378/4885 |
| US-20230219912-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | TFAM, NDUFAF1, NDUFV1 | CA12 1740/4885CA2 1266/4885CA9 2073/4885 |
| US-20250289792-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | TPX2, CBX2, RIOX2 | CA12 4694/4885CA2 1784/4885CA9 4206/4885 |
| US-20220119361-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | TPX2, MRGPRX2, CBX2 | CA12 4699/4885CA2 1458/4885CA9 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.